Aquatic Capital Management LLC Increases Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Aquatic Capital Management LLC lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 98.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 182,434 shares of the company's stock after purchasing an additional 90,634 shares during the period. Aquatic Capital Management LLC owned 0.18% of Intellia Therapeutics worth $2,127,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $43,177,000. Contrarius Group Holdings Ltd acquired a new position in Intellia Therapeutics during the fourth quarter valued at approximately $11,798,000. Trexquant Investment LP bought a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $7,785,000. Vanguard Group Inc. lifted its stake in shares of Intellia Therapeutics by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock worth $118,816,000 after buying an additional 562,249 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Intellia Therapeutics by 36.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company's stock worth $23,042,000 after acquiring an additional 528,962 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA traded up $0.20 on Friday, hitting $8.84. The company's stock had a trading volume of 3,461,561 shares, compared to its average volume of 2,413,156. The company has a 50-day simple moving average of $8.38 and a 200 day simple moving average of $11.58. The company has a market capitalization of $915.09 million, a PE ratio of -1.62 and a beta of 2.23. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.18.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of research analyst reports. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price for the company in a research note on Monday, April 21st. StockNews.com raised Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Barclays lowered their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Wells Fargo & Company cut their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Finally, The Goldman Sachs Group reiterated a "sell" rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $36.68.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.